MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Certara Inc

Geschlossen

BrancheGesundheitswesen

5.55 3.16

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.4

Max

5.65

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.4M

-5.9M

Verkäufe

-968K

104M

KGV

Branchendurchschnitt

100.714

66.418

Gewinnspanne

-5.688

Angestellte

1,515

EBITDA

8.6M

32M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+63.22% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-164M

870M

Vorheriger Eröffnungskurs

2.39

Vorheriger Schlusskurs

5.55

Nachrichtenstimmung

By Acuity

50%

50%

185 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Certara Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Apr. 2026, 17:04 UTC

Wichtige Markttreiber

FDA Rejects Replimune's Melanoma Drug for a Second Time

11. Apr. 2026, 00:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Big Yachts, Big Bucks -- Barrons.com

10. Apr. 2026, 21:55 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. Apr. 2026, 21:01 UTC

Ergebnisse

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. Apr. 2026, 20:50 UTC

Market Talk
Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

10. Apr. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. Apr. 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. Apr. 2026, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. Apr. 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. Apr. 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. Apr. 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. Apr. 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. Apr. 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10. Apr. 2026, 18:25 UTC

Market Talk
Wichtige Nachrichtenereignisse

Precious Metals Finish With Weekly Gains -- Market Talk

10. Apr. 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10. Apr. 2026, 17:31 UTC

Market Talk
Wichtige Nachrichtenereignisse

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10. Apr. 2026, 17:26 UTC

Ergebnisse

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10. Apr. 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10. Apr. 2026, 17:00 UTC

Wichtige Nachrichtenereignisse

Construction Business Taking a Hit From Iran Conflict -- WSJ

10. Apr. 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10. Apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10. Apr. 2026, 16:12 UTC

Ergebnisse

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10. Apr. 2026, 16:11 UTC

Ergebnisse

Partners Group: Traditional Programs Contributed $3.3B

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group 1Q New Client Demand $8.3B

10. Apr. 2026, 16:09 UTC

Ergebnisse

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10. Apr. 2026, 15:54 UTC

Akquisitionen, Fusionen, Übernahmen

Plenitude Completes Acquisition of Acea Energia

10. Apr. 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Certara Inc Prognose

Kursziel

By TipRanks

63.22% Vorteil

12-Monats-Prognose

Durchschnitt 8.83 USD  63.22%

Hoch 10 USD

Tief 7 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Certara Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

3

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

11.27 / 12.79Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

185 / 348 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat